Science 37 (SNCE) is an American clinical research company that specializes in Decentralized Clinical Trials. CEO David Coman weighs in on the stock beginning to trade today on the Nasdaq after a SPAC deal with LifeSci Acquisition II Corp. Approximately $235M net cash was received in the deal. How will the stock continue to perform and what is next for the now public company?
The Watch List
07 Oct 2021
SHARE
Morning Trade Live
12 Aug 2022
Market On Close
28 Sep 2022
Morning Trade Live
15 Aug 2022
Trading 360
28 Sep 2022
Trading 360
26 Jul 2022
Market On Close
15 Sep 2022